

One-pot, three-component Synthesis of pyrrolo[2,3-*d*]pyrimidine Derivatives

Ramin Javahershenas, Jabbar Khalafy*

Department of Organic Chemistry, Faculty of Chemistry, Urmia University, Urmia, Iran.

Tel/Fax: +98-44-3275-5294.

* Corresponding author's e-mail: jkhalfi@yahoo.com; j.khalafi@urmia.ac.ir

Received October 25th, 2017; Accepted February 7th, 2018.

DOI:

Abstract. A green approach for the synthesis of polyfunctionalized pyrrolo[2,3-*d*]pyrimidine derivatives was successfully achieved by a one-pot three-component reaction of arylglyoxals, 6-amino-1,3-dimethyluracil and barbituric acid derivatives in the presence of tetra-*n*-butylammonium bromide (TBAB) (5 mol%) as the catalyst in ethanol at 50 °C. This protocol has many advantages such as high yields (73-95%), green and simple procedure, short reaction times, easy work-up, mild reaction conditions and general applicability.

Keywords: 6-Amino-1,3-dimethyluracil; arylglyoxals; barbituric acid derivatives; TBAB; pyrrolo[2,3-*d*]pyrimidines; one-pot; multicomponent reactions.

Resumen. Se describe el desarrollo de una ruta sintética sustentable para la preparación de derivados pirrolo[2,3-*d*]pirimidinas mediante una reacción de tres componentes en un matraz de arilgloxales, 6-amino-1,3-dimethyluracilo y derivados del ácido barbitúrico en presencia de bromuro de tetra-*n*-butilamonio (TBAB) (5% mol) como catalizador en etanol a 50 °C. Este protocolo posee diversas ventajas, tales como elevados rendimientos (73-95%), procedimiento simple y sustentable, cortos tiempos de reacción, extracción sencilla, condiciones de reacción suaves y amplia aplicabilidad.

Palabras clave: 6-Amino-1,3-dimetiluracilo; arilgloxales; derivados del ácido barbitúrico; TBAB; pirrolo[2,3-*d*]pirimidinas; reacción multicomponente en un matraz.

Introduction

There is a worldwide demand for design and synthesis of organic compounds with biological and pharmaceutical activity [1] using readily available starting materials by one-pot multicomponent reactions (MCRs) [2]. MCRs have many advantages in comparison with classical reactions, such as easier isolation and purification, lower energy consumption, using green solvents, easy operation, and more productivity with excellent chemo- and regioselectivities [3].

Barbituric acid and uracil derivatives have an important role in medicinal chemistry because for their biological activities [4]. There are many multicomponent condensations using barbituric acid and uracil as starting materials for the rapid synthesis of heterocyclic of pyrido-, pyrrolo-, and pyrimido-pyrimidines with various biological and pharmaceutical application [5]. Examples of their use are as antimicrobial [6], acaricidal [7], anti-inflammatory [8], anticancer [9], analgesic [10], sedative [11], anticonvulsants [12] and anesthetic agents [13].

Recently tetra-*n*-butylammonium bromide (TBAB) has emerged as one of the most widely used phase transfer catalysts. It combines the lipophilicity required for an efficient phase transfer catalyst with the hydrophobicity necessary for efficient catalyst recovery [14]. This and some other related ionic liquids have considerable interest as potential ecofriendly reagents due to their low vapor pressure. These liquids dissolve in many inorganic and organic materials, are nonvolatile and nonflammable, possess high thermal, high ionic conductivity, and chemical stability. It has been successfully used in the solid-liquid or liquid-liquid phase-transfer alkylation for C-C and C-X bond formation. It has been used as an inexpensive, mild, water-tolerant, and environmentally compatible an efficient homogeneous catalyst in different organic transformations [15]. TBAB is also a cheap, simple to use, readily available ionic liquid and has inherent properties like non-corrosive nature environmental compatibility, and ease of reusability [16].


In continuation of our interest in the synthesis of new heterocyclic compounds via one-pot, multicomponent reactions [17-23], herein we report a convenient and rapid method for the synthesis of pyrrolo[2,3-*d*]pyrimidine derivatives by one-pot three-component reactions using arylglyoxals **1a-d**, 6-amino-1,3-dimethyluracil (**2**) and barbituric acid derivatives **3a-c** in the presence of a catalytic amount of TBAB (5 mol%) at 50 °C in ethanol.

Results and Discussion

In attempting to develop a simple, one-pot and short reaction pathway for the synthesis of various heterocyclic compounds, we reported earlier the synthesis of pyrazolo[3,4-*d*]pyridines, pyrazolo[3,4-*b*]quinolin-5-ones and pyrazolo[4',3':5,6]pyrido[2,3-*d*]pyridin-5,7-diones, benzo[*H*]thieno[2,3-*b*]quinolone-9-yl(aryl)methanones, 6,7-dihydro-1*H*-indole-4(5*H*)-ones, acridine-1,8(2*H*,5*H*)-diones, 1,3-dimethyl-2,4-dioxo-1,2,3,4,5,8-hexahydropyrido[2,3-*d*]pyrimidine-6-carbonitriles, pyrrolo[3,2-*d*]pyrimidines [17-23].

The reaction of arylglyoxal **1a** with **2**, and barbituric acid derivatives **3a** and **3c** in ethanol under reflux conditions to form the desired polyfunctionalized pyrrolo[2,3-*d*]pyrimidine derivatives **4e** and **4i** has been previously reported [24]. Herein we report a simpler and more efficient procedure for this reaction.

We found that the reaction of arylglyoxals **1a-d** with **2** and barbituric acid derivatives **3a-c** in the presence of TBAB (5 mol%) in ethanol at 50 °C, instead of using reflux conditions, afforded polyfunctionalized pyrrolo[2,3-*d*]pyrimidine derivatives **4a-l** in high yields with no sign of any dihydropyrido[2,3-*d*:6,5-*d'*]dipyrimidine derivatives **5a-l** formation (**Scheme 1**).



Scheme 1. Synthesis of pyrrolo[3,2-*d*]pyrimidine derivatives **4a-l**.

In our trial studies, the reaction of phenylglyoxal **1a**, **2**, and barbituric acid **3a** was chosen as a model reaction (Table 1). First, we carried out this model reaction in the absence of a catalyst, but no product was observed even after 30 min of stirring at room temperature (Table 1, entry 1). To optimize the reaction temperature, the reactions were carried out at different temperatures ranging from room temperature to reflux. It was found that the yield was improved when the temperature was increased to reflux. Refluxing the reaction mixture in EtOH without any catalyst for 30 min gave the desired product **4a** in 81% yield (Table 1, entry 3). Using 5 mol% of TBAB as organocatalyst for this reaction improved the yield (Table 1, entry 6), but using 10 mol% of TBAB for 65 min decreased the yield to 78% (Table 2, entry 9). The product was fully characterized using FT-IR (KBr), ¹H-NMR and ¹³C-NMR spectral data, and by reference to the physical data, where appropriate [24].

To optimize the reaction temperature, the reactions were carried out at different temperatures ranging from room temperature to reflux. It was found that the yield was improved and the reaction time was shortened when the temperature was increased to 50 °C.

The best result was obtained in terms of yield (90%) and reaction time (65 min) when the reaction was performed using 5 mol% of TBAB (Table 1, entry 6). To find the best solvent for this reaction, we repeated the model reaction in various solvents such as acetonitrile, dichloromethane (DCM), THF, DMF, MeOH, EtOH/H₂O (1:1) and H₂O. It was shown that EtOH was the best solvent in terms of yield and reaction time (Table 1, entry 6).

Table 1. The effect of several solvents, temperatures and mol% of TBAB in the synthesis of **4a**

Entry	Catalyst	Temperature (°C)	Solvent	Time (min)	Yield (%)
1	No Catalyst	RT	EtOH	30	trace
2	No Catalyst	50	EtOH	30	56
3	No Catalyst	Reflux	EtOH	30	81
4	TBAB (5 mol%)	RT	EtOH	65	38
5	TBAB (5 mol%)	40	EtOH	65	65
6	TBAB (5 mol%)	50	EtOH	65	90
7	TBAB (5 mol%)	60	EtOH	65	89
8	TBAB (5 mol%)	Reflux	EtOH	65	85
9	TBAB (5 mol%)	50	THF	65	36
10	TBAB (5 mol%)	50	MeOH	65	54
11	TBAB (5 mol%)	50	CH ₂ Cl ₂	65	25
12	TBAB (5 mol%)	50	CH ₃ CN	65	31
13	TBAB (5 mol%)	50	DMF	65	51
14	TBAB (5 mol%)	50	H ₂ O	65	56
15	TBAB (5 mol %)	50	EtOH/H ₂ O(1:1)	65	61

We also examined this reaction in the absence and presence of several other catalysts. When the reaction was carried out without any catalyst, the desired product **4a** was formed in 56% yield (Table 2, entry 1). The use of bases like K₂CO₃ or 1,4-diazabicyclo[2.2.2]octane (DABCO) led to no improvement in yield, while acids, *p*-toluene sulfonic acid (*p*-TSA), ZrOCl₂, sodium dodecyl sulfate (SDS), L-Proline gave small improvements (Table 2, entries 2–7). The best result was obtained when TBAB was used as a catalyst giving a yield of 90% (Table 2, entry 8).

To study the effect of the amount of catalyst, the reactions were carried out using different amounts of TBAB ranging from 5 to 10 mol%. The use of 5 mol% TBAB in EtOH led to optimum results. Using the larger amounts of TBAB did not improve the yields.

Table 2. The effect of several catalysts in the synthesis of **4a**.^a

Entry	Catalyst	Temperature (°C)	Solvent	Time (min)	Yield (%)
1	-	50	EtOH	65	56
2	K ₂ CO ₃ (5 mol%)	50	EtOH	65	49
3	DABCO (5 mol%)	50	EtOH	65	45
4	SDS (5 mol%)	50	EtOH	65	65
5	<i>p</i> -TSA (5 mol%)	50	EtOH	65	67
6	ZrOCl ₂ (5 mol%)	50	EtOH	65	69
7	L-Proline (5 mol%)	50	EtOH	65	71
8	TBAB (5 mol%)	50	EtOH	65	90
9	TBAB (10 mol%)	50	EtOH	65	78

^a Phenyglyoxal (1 mmol), barbituric acid (1 mmol) and **2** (1 mmol) in EtOH (5 mL).

The reaction times (60-80 min), yields (73-95%) and melting points (>300 °C) of synthesized pyrrolo[3,2-*d*]pyrimidine derivatives **4a-1** using 5 mole% TBAB as catalyst are shown in Table 3. The substituted pyrrolo[3,2-


d]pyrimidine derivatives **4a-l** were characterized using FT-IR, ¹H NMR and ¹³C NMR spectral data and microanalysis. In the ¹H NMR spectra of products **4a-l**, the characteristic singlets at around 11.79-12.29 and 4.55-5.32 ppm are attributed to the NH of pyrrole moiety and the CH of barbituric acid ring respectively. In the ¹³C NMR spectra of the products **4a-l**, signals located around 151.1-174.2 ppm were ascribed to the three different carbonyl groups. In the FT-IR (KBr) spectra, the characteristic absorptions bands at 1671-1703, 1634-1689 and 1549-1589 cm⁻¹ could be assigned to the vibrations of different carbonyl groups.

Table 3. Reaction conditions for the synthesis of pyrrolo[3,2-*d*]pyrimidine **4a-l**.^a

Product	Ar	R	R	Y	Time (min)	Yields (%)	Mp (°C)
4a	C ₆ H ₅	O	H	H	65	90	>300
4b	4-MeC ₆ H ₄	O	H	H	60	95	>300
4c	4-ClC ₆ H ₄	O	H	H	70	78	>300
4d	4-NO ₂ C ₆ H ₄	O	H	H	75	76	>300
4e	C ₆ H ₅	S	H	H	70	86	>300
4f	4-MeC ₆ H ₄	S	H	H	65	90	>300
4g	4-ClC ₆ H ₄	S	H	H	75	76	>300
4h	4-NO ₂ C ₆ H ₄	S	H	H	80	73	>300
4i	C ₆ H ₅	O	Me	Me	60	91	>300
4j	4-MeC ₆ H ₄	O	Me	Me	55	94	>300
4k	4-ClC ₆ H ₄	O	Me	Me	65	82	>300
4l	4-NO ₂ C ₆ H ₄	O	Me	Me	70	75	>300

^a Phenyglyoxal (1 mmol), barbituric acid (1 mmol) and **2** (1 mmol) in EtOH (5 mL), 50 °C, 65 min.

A plausible mechanism for the formation of the products **4a-l** is shown in Scheme 2. A sequence of reactions involving Knoevenagel condensation of **2** with aryglyoxals in the presence of TBAB forms the corresponding intermediate **I**. The observed products were then formed through an intermolecular condensation of intermediate **I** with barbituric acid derivatives with the ketone carbonyl group of **I** and loss of a water molecule, as shown in Scheme 2. It is expected that the use of TBAB in ethanol increases the stability of the ionized or tautomeric structures, thereby increasing the reaction rate and yields.



Scheme 2. The proposed mechanism for the one-pot, three-component reaction for the preparation of derivatives **4a-I**.

Conclusion

We have synthesized a new series of pyrrolo[2,3-*d*]pyrimidine derivatives **4a-l** in high yields, by the one-pot three-component reaction of arylglyoxals **1a-d** with 1,3-dimethyl-6-aminouracil **2** and barbituric acid derivatives **3a-c** using 5 mol% TBAB as the catalyst in ethanol at 50 °C. The simplicity of the method, ease of product isolation, mild reaction conditions, high yields, short reaction times and availability of the starting materials are the advantages of this procedure. Our method provides a simple synthesis of polyfunctionalized pyrrolo[2,3-*d*]pyrimidine derivatives with different substituents, which may have pharmaceutical and biological applications.

Experimental

The chemicals used in this work were purchased from Acros and Merck companies and were used without purification. Freshly distilled solvents were used throughout and anhydrous solvents were dried according to Perrin and Armarego [25]. Melting points were measured on an Electrothermal 9200 apparatus and are uncorrected. FT-IR (KBr) spectra were recorded on a Thermo Nicolet (Nexus 670) spectrometer using KBr discs. ¹H (300 MHz) and ¹³C (75.5 MHz) NMR spectra were recorded on a Bruker DRX-300 Avance spectrometer in DMSO-*d*₆ with TMS as the internal reference. Elemental analyses were performed using a Leco Analyzer 932. The arylglyoxals were prepared as their hydrates by oxidation of the corresponding acetophenones with SeO₂ [22].

General procedure for synthesis of pyrrolo[2,3-*d*]pyrimidine derivatives

A mixture of arylglyoxals **1a-d** (1 mmol), 1,3-dimethyl-6-aminouracil (**2**) (155 mg, 1 mmol) and barbituric acid derivatives **3a-c** (1 mmol), TBAB (16 mg, 0.05 mmol) in ethanol (5 ml) was stirred at 50 °C for the appropriate time as indicated in Table 3. The reaction was monitored by thin-layer chromatography TLC using (EtOAc/hexane, 5:1) as eluent. After completion of the reaction, the solid precipitate was filtered, washed with cold water and dried. Recrystallization from ethanol gave the desired products in 73-95% yields in Table 3.

5-(6-(Phenyl)-1,3-dimethyl-2,4-dioxo-2,3,4,7-tetrahydro-1*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)pyrimidine-

2,4,6(1*H*,3*H*,5*H*)-trione (4a). White powder; 343 mg; mp >300 °C; FT-IR (KBr) ν_{\max} 3468, 3173, 3066, 2954, 1671, 1655, 1563, 1444, 1394, 1305, 1097, 1114, 1021, 979, 842, 748 cm⁻¹; ¹H NMR (DMSO-*d*₆, 300 MHz) δ 11.85 (1H, s, exchanged by D₂O addition, NH), 11.17 (2H, s, exchanged by D₂O addition, 2×NH), 7.55 (2H, d, *J* = 6.9 Hz, Ar), 7.48 (2H, t, *J* = 7.2 Hz, Ar), 7.39 (1H, d, *J* = 6.6 Hz, Ar), 5.00 (1H, s, CH), 3.50 (3H, s, 3-Me), 3.15 (3H, s, 1-Me); ¹³C NMR (DMSO-*d*₆, 75.5 MHz) δ 169.7 (C=O carbonyl), 159.1 (C=O carbonyl), 151.1 (C=O carbonyl), 139.7, 131.9, 130.9, 130.1, 129.7, 129.2 and 128.5 (aromatic C), 108.9 and 97.5 (pyrrole C), 48.1 (CH), 29.8 and 27.7 (CH₃). Anal. Calcd for C₁₈H₁₅N₅O₅: C, 56.69; H, 3.96; N, 18.37. Found: C, 56.76; H, 4.11; N, 18.30.

5-(6-(4-Methylphenyl)-1,3-dimethyl-2,4-dioxo-2,3,4,7-tetrahydro-1*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)pyrimidine-

2,4,6(1*H*,3*H*,5*H*)-trione (4b). White powder; 375 mg; mp >300 °C; FT-IR (KBr) ν_{\max} 3410, 3226, 3114, 2958, 1702, 1652, 1561, 1443, 1357, 1241, 1041, 974, 818 cm⁻¹; ¹H NMR (DMSO-*d*₆, 300 MHz) δ 11.79 (1H, s, exchanged by D₂O addition, NH), 11.16 (2H, s, exchanged by D₂O addition, 2×NH), 7.42 (2H, bs, Ar), 7.29 (2H, bs, Ar), 4.96 (1H, s, CH), 3.47 (3H, s, 3-Me), 3.15 (3H, s, 1-Me), 2.34 (3H, s, Me); ¹³C NMR (DMSO-*d*₆, 75.5 MHz) δ 169.7 (C=O carbonyl), 159.1 (C=O carbonyl), 151.0 (C=O carbonyl), 139.5, 131.9, 130.3, 129.8, 129.7, 129.0 and 128.4 (aromatic C), 108.5

and 97.4 (pyrrole C), 47.0 (CH), 31.1, 28.9 and 21.2 (CH₃). Anal. Calcd for C₁₉H₁₇N₅O₅: C, 57.72; H, 4.33; N, 17.71. Found: C, 57.79; H, 4.25; N, 17.81.

5-(6-(4-Chlorophenyl)-1,3-dimethyl-2,4-dioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (4c). Pale yellow powder; 324 mg; mp >300 °C; FT-IR (KBr) ν_{\max} 3412, 3209, 2955, 1702, 1655, 1564, 1495, 1438, 1361, 1248, 1097, 1031, 977, 809, 505 cm⁻¹; ¹H NMR (DMSO-*d*₆, 300 MHz) δ 11.91 (1H, s, exchanged by D₂O addition, NH), 11.20 (2H, s, exchanged by D₂O addition, 2×NH), 7.54 (4H, bs, Ar), 5.01 (1H, s, CH), 3.45 (3H, s, 3-Me), 3.14 (3H, s, 1-Me); ¹³C NMR (DMSO-*d*₆, 75.5 MHz) δ 169.5 (C=O carbonyl), 159.1 (C=O carbonyl), 151.1 (C=O carbonyl), 139.6, 133.0, 130.6, 130.1, 129.7, 129.2 and 129.1 (aromatic C), 111.5 and 101.1 (pyrrole C), 46.9 (CH), 31.0 and 27.8 (CH₃). Anal. Calcd for C₁₈H₁₄ClN₅O₅: C, 52.00; H, 3.39; N, 16.84. Found: C, 51.92; H, 3.45; N, 16.90.

5-(6-(4-Nitrophenyl)-1,3-dimethyl-2,4-dioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (4d). Orange powder: 324 mg; mp >300 °C; FT-IR (KBr) ν_{\max} 3442, 3392, 3139, 2963, 1642, 1589, 1438, 1328, 1438, 1328, 1218, 1148, 1118, 976, 580, 743, 706, 638 cm⁻¹; ¹H NMR (DMSO-*d*₆, 300 MHz) δ 12.16 (1H, s, exchanged by D₂O addition, NH), 11.28 (2H, s, exchanged by D₂O addition, 2×NH), 8.26 (2H, d, *J* = 7.8 Hz, Ar), 7.74 (2H, d, *J* = 7.8 Hz, Ar), 5.17 (1H, s, CH), 3.44 (3H, s, 3-Me), 3.13 (3H, s, 1-Me); ¹³C NMR (DMSO-*d*₆, 75.5 MHz) δ 169.3 (C=O carbonyl), 159.0 (C=O carbonyl), 151.2 (C=O carbonyl), 140.6, 132.7, 132.3, 129.7, 128.7, 128.3 and 127.4 (aromatic C), 111.9 and 98.2 (pyrrole C), 47.6 (CH), 31.1 and 27.8 (CH₃). Anal. Calcd for C₁₈H₁₄N₆O₇: C, 50.71; H, 3.31; N, 19.71. Found: C, 50.63; H, 3.40; N, 19.81.

6-(Phenyl)-5-(4,6-dioxo-2-thioxohexahydropyrimidin-5-yl)-1,3-dimethyl-1,7-dihydro-2H-pyrrolo[2,3-*d*]pyrimidine-2,4(3H)-dione (4e). Pale pink powder: 341 mg; mp >300 °C (Lit.[24] >350°C); FT-IR (KBr) ν_{\max} 3354, 3178, 2257, 1648, 1550, 1439, 1300, 1219, 1154, 1006, 761, 696, 539 cm⁻¹; ¹H NMR (DMSO-*d*₆, 300 MHz) δ 12.29 (1H, s, exchanged by D₂O addition, NH), 11.94 (1H, s, exchanged by D₂O addition, NH), 11.66 (1H, s, exchanged by D₂O addition, NH), 7.41 (2H, d, *J* = 7.2 Hz, Ar), 7.26 (2H, t, *J* = 6.9 Hz, Ar), 7.16 (1H, d, *J* = 6.6 Hz, Ar), 5.20 (1H, s, CH), 3.44 (3H, s, 3-Me), 3.15 (3H, s, 1-Me); ¹³C NMR (DMSO-*d*₆, 75.5 MHz) δ 173.8 (C=S), 161.3 (C=O carbonyl), 158.4 (C=O carbonyl), 151.9 (C=O carbonyl), 139.8, 132.1, 129.7, 129.5 and 129.2 (aromatic C), 106.8 and 100.2 (pyrrole C), 48.9 (CH), 30.9 and 27.8 (CH₃). Anal. Calcd for C₁₈H₁₅N₅O₄S: C, 54.40; H, 3.80; N, 17.62. Found: C, 54.49; H, 3.71; N, 17.70.

6-(Methylphenyl)-5-(4,6-dioxo-2-thioxohexahydropyrimidin-5-yl)-1,3-dimethyl-1,7-dihydro-2H-pyrrolo[2,3-*d*]pyrimidine-2,4(3H)-dione (4f). Pale pink powder: 370 mg; mp >300 °C; FT-IR (KBr) ν_{\max} 3399, 3183, 3057, 2923, 2854, 1692, 1650, 1554, 1435, 1360, 1237, 1157, 1040, 1005, 875, 763, 743, 629, 534 cm⁻¹; ¹H NMR (DMSO-*d*₆, 300 MHz) δ 12.28 (s, 1H, exchanged by D₂O addition, NH), 11.75 (1H, s, exchanged by D₂O addition, NH), 11.61 (1H, s, exchanged by D₂O addition, NH), 7.21 (2H, bs, Ar), 6.96 (2H, bs, Ar), 4.66 (1H, s, CH), 3.36 (3H, s, 3-Me), 3.15 (3H, s, 1-Me), 2.31 (3H, s, Me); ¹³C NMR (DMSO-*d*₆, 75.5 MHz) δ 173.6 (C=O), 161.6 (C=O carbonyl), 158.3 (C=O carbonyl), 151.0 (C=O carbonyl), 139.7, 132.2, 132.1, 129.6, 129.4 and 128.9 (aromatic C), 107.0 and 98.3 (pyrrole C), 49.0 (CH), 30.8, 29.7 and 23.5 (CH₃). Anal. Calcd for C₁₉H₁₇N₅O₄S: C, 55.47; H, 4.16; N, 17.02. Found: C, 55.40; H, 4.26; N, 17.10.

6-(4-Chlorophenyl)-5-(4,6-dioxo-2-thioxohexahydropyrimidin-5-yl)-1,3-dimethyl-1,7-dihydro-2H-pyrrolo[2,3-d]pyrimidine-2,4(3H)-dione (4g). Pale pink powder: 328 mg; mp >300 °C; FT-IR (KBr) ν_{\max} 3359, 3195, 2959, 1648, 1549, 1433, 1378, 1296, 1221, 1152, 1006, 978, 787, 738, 668, 539 cm^{-1} ; ^1H NMR (DMSO- d_6 , 300 MHz) δ 12.29 (1H, s, exchanged by D₂O addition, NH), 12.06 (1H, s, exchanged by D₂O addition, NH), 11.72 (1H, s, exchanged by D₂O addition, NH), 7.43 (2H, d, $J = 7.8$ Hz, Ar), 7.39 (2H, d, $J = 7.8$ Hz, Ar), 4.68 (1H, s, CH), 3.45 (3H, s, 3-Me), 3.16 (3H, s, 1-Me); ^{13}C NMR (DMSO- d_6 , 75.5 MHz) δ 174.0 (C=S), 161.9 (C=O carbonyl), 158.3 (C=O carbonyl), 152.0 (C=O carbonyl), 140.2, 131.7, 131.0, 128.7, 128.6 and 128.3 (aromatic C), 107.3 and 100.1 (pyrrole C), 49.0 (CH), 29.7 and 27.8 (CH₃). Anal. Calcd for C₁₈H₁₄ClN₅O₄S: C, 50.06; H, 3.27; N, 16.22. Found: C, 50.13; H, 3.35; N, 16.13.

6-(4-Nitrophenyl)-5-(4,6-dioxo-2-thioxohexahydropyrimidin-5-yl)-1,3-dimethyl-1,7-dihydro-2H-pyrrolo[2,3-d]pyrimidine-2,4(3H)-dione (4h). Orange powder: 323 mg; mp >300 °C; FT-IR (KBr) ν_{\max} 3400, 3209, 2955, 1702, 1689, 1615, 1495, 1364, 1221, 1095, 827, 744, 514 cm^{-1} ; ^1H NMR (DMSO- d_6 , 300 MHz) δ 12.21 (2H, s, exchanged by D₂O addition, 2×NH), 11.86 (1H, s, exchanged by D₂O addition, NH), 8.10 (2H, d, $J = 7.8$ Hz, Ar), 7.62 (2H, d, $J = 7.8$ Hz, Ar), 4.55 (1H, s, CH), 3.42 (3H, s, 3-Me), 3.14 (3H, s, 1-Me); ^{13}C NMR (DMSO- d_6 , 75.5 MHz) δ 174.1 (C=S), 161.0 (C=O carbonyl), 158.2 (C=O carbonyl), 150.9 (C=O carbonyl), 141.1, 131.6, 127.5, 126.5, 125.0 and 122.8 (aromatic C), 110.4 and 100.9 (pyrrole C), 48.1 (CH), 31.0 and 27.8 (CH₃). Anal. Calcd for C₁₈H₁₄N₆O₆S: C, 48.98; H, 3.08; N, 19.11. Found: C, 48.87; H, 3.19; N, 19.00.

5-(6-(Phenyl)-1,3-dimethyl-2,4-dioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (4i). White powder: 372 mg; mp >300 °C (Lit.[24] >350°C); FT-IR (KBr) ν_{\max} 3450, 3177, 2963, 1691, 1640, 1565, 1495, 1372, 1248, 1091, 1053, 975, 819, 742, 517 cm^{-1} ; ^1H NMR (DMSO- d_6 , 300 MHz) δ 11.90 (1H, s, exchanged by D₂O addition, NH), 7.35-7.65 (5H, m, Ar), 5.15 (1H, s, CH), 3.50 (3H, s, Me), 3.16 (6H, s, 2xMe), 3.13 (3H, s, Me); ^{13}C NMR (DMSO- d_6 , 75.5 MHz) δ 168.1 (C=O carbonyl), 159.3 (C=O carbonyl), 152.4 (C=O carbonyl), 151.1 (C=O carbonyl), 139.7, 131.6, 130.8, 129.6 and 128.5 (aromatic C), 109.2 and 97.3 (pyrrole C), 47.1 (CH), 31.1, 29.3 and 28.9 (CH₃). Anal. Calcd for C₂₀H₁₉N₅O₅: C, 58.68; H, 4.68; N, 17.11. Found: C, 58.60; H, 4.77; N, 17.19.

5-(6-(4-Methylphenyl)-1,3-dimethyl-2,4-dioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (4j). White powder: 398 mg; mp >300 °C; FT-IR (KBr) ν_{\max} 3745, 3459, 2938, 1691, 1634, 1446, 1344, 1215, 1107, 1033, 905, 760, 631 cm^{-1} ; ^1H NMR (DMSO- d_6 , 300 MHz) δ 11.85 (1H, s, exchanged by D₂O addition, NH), 7.38 (2H, d, $J = 7.5$ Hz, Ar), 7.13 (2H, d, $J = 7.5$ Hz, Ar), 5.16 (1H, s, CH), 3.52 (3H, s, 3-Me), 3.33 (3H, s, 1-Me), 3.05 (6H, s, 1-Me, 3-Me), 2.26 (3H, s, Me); ^{13}C NMR (DMSO- d_6 , 75.5 MHz) δ 167.8 (C=O carbonyl), 159.2 (C=O carbonyl), 152.3 (C=O carbonyl), 151.0 (C=O carbonyl), 140.7, 132.1, 129.7 129.3 and 129.3 (aromatic C), 112.1 and 100.6 (pyrrole C), 47.7 (CH), 31.2, 28.9, 27.9 and 21.2 (CH₃). Anal. Calcd for C₂₁H₂₁N₅O₅: C, 59.57; H, 5.00; N, 16.54. Found: C, 59.45; H, 5.00; N, 16.62.

5-(6-(4-Chlorophenyl)-1,3-dimethyl-2,4-dioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (4k). Pale yellow powder: 364 mg; mp >300 °C; FT-IR (KBr) ν_{\max} 3392, 3220, 3108, 2951, 2875, 1703, 1651, 1562, 1443, 1359, 1241, 1038, 975, 816, 774, 702, 608, 502 cm^{-1} ; ^1H NMR

(DMSO-*d*₆, 300 MHz) δ 11.95 (1H, s, exchanged by D₂O addition, NH), 7.57 (4H, bs, Ar), 5.16 (1H, s, CH), 3.49 (3H, s, 3-Me), 3.16 (6H, s, 1-Me, 3-Me), 2.50 (3H, s, Me); ¹³C NMR: (DMSO-*d*₆, 75.5 MHz) δ 168.0 (C=O carbonyl), 159.2 (C=O carbonyl), 152.4 (C=O carbonyl), 139.9, 133.1, 130.4, 130.1, 129.6 and 129.3 (aromatic C), 109.7 and 101.0 (pyrrole C), 47.2 (CH), 31.1, 30.4 and 28.9 (CH₃). Anal. Calcd for C₂₀H₁₈ClN₅O₅: C, 54.12; H, 4.09; N, 15.78. Found: C, 54.20; H, 4.16; N, 15.70.

5-(6-(4-Nitrophenyl)-1,3-dimethyl-2,4-dioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-*d*]pyrimidin-5-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (4I). Orange powder: 341 mg; mp >300 °C; FT-IR (KBr) ν_{\max} 3178, 3069, 2940, 1700, 1670, 1581, 1514, 1444, 1341, 1109, 979, 860, 752, 706 cm⁻¹; ¹H NMR (DMSO-*d*₆, 300 MHz) δ 12.15 (1H, s, exchanged by D₂O addition, NH), 8.34 (2H, d, *J* = 8.4 Hz, Ar), 7.80 (2H, d, *J* = 8.4 Hz, Ar), 5.32 (1H, s, CH), 3.51 (3H, s, 3-Me), 3.15 (6H, s, 1-Me, 3-Me), 2.50 (3H, s, Me); ¹³C NMR: (DMSO-*d*₆, 75.5 MHz) δ 167.8 (C=O carbonyl), 159.2 (C=O carbonyl), 152.3 (C=O carbonyl), 151.0 (C=O carbonyl), 140.7, 132.0, 129.7, 129.6 and 129.3 (aromatic C), 112.1 and 102.7 (pyrrole C), 47.7 (CH), 31.2, 28.9 and 27.9 (CH₃). Anal. Calcd for C₂₀H₁₈N₆O₇: C, 52.87; H, 3.99; N, 18.50. Found: C, 52.73; H, 4.05; N, 18.63.

ACKNOWLEDGMENT

We are grateful to Urmia University for financial support. We also thank Professor R.H. Prager from Flinders University, Australia for proof-reading and language editing of manuscript.

REFERENCES

1. (a) Khodabakhshi, S.; Karimi, B. *New J. Chem.* **2014**, 38, 3586-3590. (b) Bagdi, A.; Hajra, A. *RSC Adv.* **2014**, 4, 23287-23291. (c) Ma, L. Y.; Zheng, Y. C.; Wang, S. Q.; Wang, B.; Wang, Z. R.; Pang, L. P.; Zhang, M.; Wang, J. W.; Ding, L.; Li, J.; Wang C.; Hu, B.; Liu, Y.; Zhang, X. D.; Wang, J. J.; Wang, Z. J.; Zhao, W.; Liu, H. M. *J. Med. Chem.* **2015**, 58, 1705-1716.
2. (a) Mahmudov, K. T.; Kopylovich, M. N.; Maharramov, A. M.; Kurbanova, M. M.; Gurbanov, A. V.; Pombeiro, A. J. L.; *Coord. Chem. Rev.* **2014**, 265, 1-37. (b) Chanda, A.; Fokin, V. V. *Chem. Rev.* **2009**, 109, 725-748. (c) Allias, C.; Grassot, J.; Rodriguez, J.; Constantieux, T. *Chem. Rev.* **2014**, 114, 10829-10868. (d) Domling, A.; Wang, W.; Wang, K. *Chem. Rev.* **2012**, 12, 3083-3135.
3. (a) Jiang, S.; Gao, J.; Han, L. *Res. Chem. Intermed.* **2016**, 2, 1017-1028. (b) Teimuri-Mofrad, R.; Shahrissa, A.; Gholamhosseini-Nazari, M.; Arsalani, N. *Res. Chem. Intermed.* **2016**, 42, 3425-3439. (c) Nikoofar, K.; Khademi, Z. *Res. Chem. Intermed.* **2016**, 42, 3929-3977. (d) Ershov, O. V.; Ievler, M. Y.; Tafeenko, V. A.; Nasakin, O. E. *Green Chem.* **2015**, 17, 4234-4238. (e) Vidadala, S. R.; Waldmann, H. *Tetrahedron Lett.* **2015**, 56, 3358-3360. (f) Peck, C. L.; Calderone, J. A.; Santos, W. L. *Synthesis* **2015**, 47, 2242-2248. (g) Fu, Z.; Qian, K.; Li, S.; Shen, T. *Tetrahedron Lett.* **2016**, 57, 1104-1108.
4. (a) Ma, L.; Li, S.; Zheng, H.; Chen, J.; Lin, L.; Ye, X.; Chen, Zhizhi.; Xu, Q.; Chen, T.; Yang, J.; Qiu, N.; Wang, G.; Peng, A.; Ding, Y.; Wei, Y.; Chen, L. *Eur. J. Med. Chem.* **2011**, 46, 2003-2010. (b) Edupuganti, R.; Wang, Q.; Tavares, C. D. J.; Chitjian, C. A.; Bachman, J. L.; Ren, P.; Anslyn, E. V.; Dalby, K. N. *Bioorg. Med. Chem.* **2014**, 22, 4910-4916. (c) Pałasz, A.; Cież, D. *Eur. J. Med. Chem.* **2015**, 97, 582-611.

5. (a) Tolstoluzhsky, N.; Nikolaienko, P.; Gorobets, N.; Van der Eycken, E. V.; Kolos, N. *Eur. J. Org. Chem.* **2013**, 2013, 5364-5369. (b) Sisa, M.; Pla, D.; Altuna, M.; Francesch, A.; Cuevas, C.; Albericio, F.; Alvarez, M. *J. Med. Chem.* **2009**, 52, 6217-6223. (c) Giraud, F.; Alves, G.; Debiton, E.; Nauton, L.; Thery, V.; Durieu, E.; Ferandin, Y.; Lozach, O.; Meijer, L.; Anizon, F.; Pereira, E.; Moreau, P. *J. Med. Chem.* **2011**, 54, 4474-4489.
6. Dhorajiya, B. D.; Dholakiya, B. Z.; Mohareb, R. M. *Med. Chem. Res.* **2014**, 23, 3941-3952.
7. Yagi, K.; Akimoto, K.; Mimori, N.; Miyake, T.; Kudo, M.; Arai, K.; Ishii, S. *Pest Manage. Sci.* **2000**, 56, 65-73.
8. (a) Isobe, Y.; Tobe, M.; Inoue, Y.; Isobe, M.; Tsuchiya, M.; Hayashi, H. *Bioorg. Med. Chem.* **2003**, 11, 4933-4940. (b) El-Gazzar, A. R. B. A.; Hafez, H. N. *Bioorg. Med. Chem. Lett.* **2009**, 19, 3392-3397.
9. (a) Siddiqui, Z. N. *Tetrahedron Lett.* **2015**, 56, 1919-1924. (b) Singh, P.; Kaur, M.; Verma, P. *Bioorg. Med. Chem. Lett.* **2009**, 19, 3054-3058. (c) Dhorajiya, B. D.; Dholakiya, B. Z.; Mohareb, R. M. *Med. Chem. Res.* **2014**, 23, 3941-3952.
10. Abu-Hashem, A. A.; Gouda, M. A.; Badria, F. A. *Eur. J. Med. Chem.* **2010**, 45, 1976-1981.
11. Kliethermes, C. L.; Metten, P.; Belknap, J. K.; Buck, K. J.; Crabbe, J. C. *Brain Res.* **2004**, 1009, 17-25.
12. (a) Archana, V. K.; Srivastava, Kumar, A. *Bioorg. Med. Chem.* **2004**, 12, 1257-1264. (b) Mahmudov, K. T.; Kopylovich, M. N.; Maharramov, A. M.; Kurbanov, M. M. *Int. J. Res. Pharm. Biomed. Sci.* **2011**, 2, 842-845.
13. Sandberg, F. *Acta Physiol. Scand.* **1951**, 24, 7-26.
14. (a) Starks, C. M.; Liotta, C. L.; Halpern, M. *Phase-Transfer Catalysis*; Chapman & Hall: New York, 1994. (b) *Handbook of Phase-Transfer Catalysis*; Sasson, Y.; Neumann, R. (Eds.); Blackie Academic & Professional: London, 1997. (c) *Phase Transfer Catalysis*; Halpern, M. E. (Ed.); ACS Symposium Series 659; American Chemical Society: Washington, DC, 1997. (d) Dehmlow, E. V.; Dehmlow, S. S. *Phase Transfer Catalysis*; 3rd ed.; VCH: Weinheim, 1993.
15. (a) Kantevari, S.; Chary, M. V.; Das, A. P. R.; Vuppallapati, S. V. N.; Lingaiah, N. *Catal. Commun.* **2008**, 9, 1575-1578. (b) Chary, M. V.; Keerthysri, N. C.; Vapallapati, S. V. N.; Lingaiah, N.; Kantevari, S. *Catal. Commun.* **2008**, 9, 2013-2017. (c) Ronchin, L.; Vavasori, A.; Amadio, E.; Cavinato, G.; Toniolo, L. *J. Mol. Catal. A: Chem.* **2009**, 298, 23-30.
16. Siddiqui, S. A.; Narkhede, U. C.; Palimkar, S. S.; Daniel, T.; Loholi, R. J.; Srinivasan, K. V. *Tetrahedron*, **2005**, 61, 3539-3546. (b) Amantini, D.; Fringuelli, F.; Pizzo, F.; Vaccaro, L. *J. Org. Chem.* **2001**, 66, 6734-6737. (c) Khurana, J. M.; Kumar, S. *Tetrahedron Lett.* **2009**, 50, 4125-4127.
17. Khalafy, J.; Majidi Arlan, F.; Soleimani Chalanchi, Sh. *J. Heterocycl. Chem.* **2018**, 55, 149-153.
18. Ezzati, M.; Khalafy, J.; Poursattar Marjani, A.; Prager, R. H. *Tetrahedron* **2017**, 73, 6587-6596.
19. Poursattar Marjani, A.; Khalafy, J.; Rostampoor, A. *J. Heterocycl. Chem.* **2017**, 54, 648-652.
20. Khalafy, J.; Badparvar, F.; Poursattar Marjani, A. *J. Chil. Chem. Soc.* **2016**, 61, 3112-3115.
21. Poursattar Marjani, A.; Khalafy, J.; Chitan, M.; Mahmoodi, S. *Iran. J. Chem. Chem. Eng.* **2017**, 36, 1-6.
22. Javahershenas, R.; Khalafy, J. *J. Heterocycl. Chem.* **2017**, 54, 3163-3168.
23. Javahershenas, R.; Khalafy, J. *Heterocycl. Commun.* **2018**, 24(1), 37-42.
24. Dommaraju, Y.; Borthakur, S.; Rajesh, N.; Prajapati, D. *RSC Adv.* **2015**, 5, 24327-24335.

25. Perrin, D. D.; Armarego, W. L. F. *Purification of Laboratory Chemicals*, Pergamon Press: Oxford, U.K., 1988.